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Abstract
Background: Glioblastoma (GB) is the most common and lethal type of primary brain tumor. Clinical outcome remains poor
and is essentially palliative due to the highly invasive nature of the disease. A more thorough understanding of the
molecular mechanisms that drive glioma invasion is required to limit dispersion of malignant glioma cells.
Methodology/Principal Findings: We investigated the potential role of differential expression of microRNAs (miRNA) in
glioma invasion by comparing the matched large-scale, genome-wide miRNA expression profiles of migrating and
migration-restricted human glioma cells. Migratory and migration-restricted cell populations from seven glioma cell lines
were isolated and profiled for miRNA expression. Statistical analyses revealed a set of miRNAs common to all seven glioma
cell lines that were significantly down regulated in the migrating cell population relative to cells in the migration-restricted
population. Among the down-regulated miRNAs, miR-23b has been reported to target potential drivers of cell migration
and invasion in other cell types. Over-expression of miR-23b significantly inhibited glioma cell migration and invasion. A
bioinformatics search revealed a conserved target site within the 39 untranslated region (UTR) of Pyk2, a non-receptor
tyrosine kinase previously implicated in the regulation of glioma cell migration and invasion. Increased expression of miR-
23b reduced the protein expression level of Pyk2 in glioma cells but did not significantly alter the protein expression level of
the related focal adhesion kinase FAK. Expression of Pyk2 via a transcript variant missing the 39UTR in miR-23b-expressing
cells partially rescued cell migration, whereas expression of Pyk2 via a transcript containing an intact 39UTR failed to rescue
cell migration.
Conclusions/Significance: Reduced expression of miR-23b enhances glioma cell migration in vitro and invasion ex vivo via
modulation of Pyk2 protein expression. The data suggest that specific miRNAs may regulate glioma migration and invasion
to influence the progression of this disease.
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Introduction
Glioblastoma (GB) is the most common adult brain tumor and
is characterized by its extensive infiltration into normal brain
tissue. This aggressive invasion effectively precludes complete
surgical resection and all but assures recurrent tumor growth.
Moreover, invading glioma cells reduce transcription of proapop-
totic and proliferation genes [1] concordant with decreased
susceptibility to cytotoxic agents [2,3] providing them with an
additional mechanism for resisting current radiological and
chemotherapeutic treatment regimens. Malignant cells can invade
over a significant distance in the brain parenchyma, commonly
along extracellular matrices of blood vessels and nerve fiber tracts
to initiate additional tumor growth. Notably, this invasive
characteristic is not shared by nonglial cells that metastasize to
the brain from other primary tumor sites highlighting the unique
biology of invasive glioma cells. This behavior carries with it a very
poor clinical prognosis. The median survival of GB patients
following diagnosis is 15 months with an overall five-year survival
of just under 10% [4]. Therefore, a more thorough understanding
of the molecular mechanisms that drive glioma invasion is
required to develop more effective therapeutic treatment [5].
Global gene expression profiling of glioblastoma has provided
substantial insights into genetic alterations in GB and fundamental
signaling pathways [6,7,8]. Importantly, these genetic alterations
have helped establish a molecular classification of GB into distinct
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response to current treatment regimens [9,10]. Less well charac-
terized is the specific set of genes that serve as drivers of the
invasive phenotype of GB. In previous studies, we investigated the
transcriptome of migratory glioma cells in vitro [1] and from
invasive cells in situ [11,12] to identify a set of genes differentially
expressed in invading glioma cells. Comprehensive analysis of the
transcriptome profiles of matched populations of migratory and
stationary glioma cells produced an invasion signature that was
validated at the transcriptional and translational levels in clinical
samples [13]. Functional validation of these genes in glioma
migration and invasion suggests potential unique targets to
specifically inhibit the invasive glioma cell population.
The molecular mechanisms initiating or regulating the expres-
sion of potential drivers of glioma invasion remain very poorly
defined. MicroRNAs (miRNAs) are a class of endogenous, small,
non-protein coding RNA molecules that serve as post-transcrip-
tional regulators of gene expression. More than 1200 human
miRNAs have been identified and many play important roles in
diverse biological processes, including cellular proliferation, cell
motility, cell cycle determination, differentiation, apoptosis,
neuronal patterning, and development [14,15]. Alterations in
specific miRNA expression levels have been identified in a number
of cancers where they may function to either inhibit the expression
of tumor suppressor genes or by allowing increased expression of
oncogenes [15]. Several studies have identified various miRNAs
that have potential functional importance in GB [16,17,18]. miR-
21 is overexpressed in GB and is linked to increased tumor growth
through an inhibition of apoptosis [19]. Similarly, increased
expression of miR-221 in GB is associated with aberrant cell cycle
progression and increased proliferation [20,21]. miRNA expres-
sion profiling has also demonstrated reduced expression of several
miRNAs in GB including miR-7, miR-128, miR124, miR137, and
miR-218 which have been linked to alterations in proliferation,
differentiation, invasion, and stem cell self-renewal [18,22,23].
To investigate the regulatory mechanisms governing the
invasive signature and to prioritize our investigation of potential
gene candidates regulating glioma cell migration and invasion, we
analyzed miRNA expression profiles in matched populations of
migrating cells versus migration-restricted cells in seven well-
established glioma cell lines. Data analysis revealed 72 consistently
differentially expressed miRNAs that exhibited similar expression
patterns in all seven glioma cell lines with a smaller conserved set
of miRNAs that were down regulated in the migrating cell
population. Among the miRNAs significantly down regulated in
the invasive cell population in vitro was miR-23b which was also
down regulated in the invasive edge in situ in clinical GB
specimens. One of the predicted targets for miR-23b is the focal
adhesion kinase Pyk2 that we have previously identified as an
important regulator of glioma cell migration [24,25]. In this
report, we confirm that Pyk2 is targeted by miR-23b and
demonstrate that increased expression of miR-23b inhibits glioma
cell migration in vitro and invasion ex vivo while knockdown of miR-
23b stimulates glioma cell migration. Increased expression of miR-
23b reduced Pyk2 expression suggesting that reduced expression of
miR-23b facilitates the enhancement of glioma cell migration and
invasion via modulation of Pyk2 expression. Identification of
miRNAs associated with glioma migration and defining the
mechanistic basis of their modulation of the invasive phenotype
may provide insights into potential targets for novel therapeutic
strategies aimed at limiting glioma invasion and improved clinical
outcomes.
Materials and Methods
Cell culture
Human glioblastoma cell lines A172, T98G, U87, SNB19,
U251 (American Type Culture Collection), SF767 (University of
California at San Francisco), G112MS [26] and 293T packaging
cells were maintained in Dulbecco’s modified Eagle’s medium
(DMEM), supplemented with 10% fetal calf serum in a 37uC, 5%
CO2 atmosphere at constant humidity.
Reagents, antibodies, and immunoblot analysis
Human placental laminin, the anti-FLAG M2 monoclonal
antibody, and anti-actin antibody were obtained from Sigma (St.
Louis, MO). Affinity purified polyclonal anti-Pyk2 and anti-FAK
antibodies were obtained from Upstate Biotechnology (Lake
Placid, NY). Immunoblotting of cellular lysates was performed
as previously described [27].
Radial cell migration assay and isolation of migratory and
stationary cell populations
The radial cell migration assay was performed as previously
described [28,29]. Briefly, three thousand cells were seeded as
a defined, confluent circular monolayer using a cell sedimentation
manifold (CSM, Inc. Phoenix, AZ) on laminin coated 10-well
slides. Sixteen hours after seeding the manifold was removed and
the cells were allowed to migrate for 24 hours. The migration rates
were estimated from photomicrographs (Axiovert, Carl Zeiss Inc.,
NY) of the diameter of the cell colony taken at the time of
manifold removal (time point 0 hours) and at time point 24 hours
using image analysis software (Scion Image, Frederick, MD).
Isolation of a GB migratory front (rim) and stationary core was
performed as previously described [13]. Stationary core and
migratory rim cell populations were harvested under an inverted
microscope (Axiovert 100, Carl Zeiss Inc., NY) using a P2 pipette
in three independent biological replicates. Thirty individual
dispersion assays (three 10-well slides) were collected per cell line
and subjected to total RNA, including small RNA, isolation.
In certain experiments, glioma cells were seeded in a 6-well
plate at 70% confluence and transfected with 100 nM of anti-
miR-23b or anti-miR negative control oligonucleotides (Ambion,
Austin, TX). At 16 hours post-transfection, cells were recovered in
DMEM +10% FBS and seeded for cell migration assay as
described above. Transfection efficiency was confirmed by
quantitative PCR 48 hours after transfection.
Clinical Samples and Histology
Fresh human glioblastoma specimens (WHO Grade IV) were
collected from patients following informed written consent at
Abbott Northwestern Hospital. Samples were submitted to the
study under a protocol approved by the Western Institutional
Review Board (protocol #20110995). Samples were obtained
from patients who underwent primary therapeutic subtotal or total
tumor resection performed under image guidance. All tissue
samples were obtained at primary resection, and none of the
patients had undergone prior chemotherapy or radiation therapy.
The samples were immediately frozen on dry ice and cut into 12-
mm sections. Histological diagnosis of tumor core and invasive
edge was made by neuropathological review by standard light-
microscopic evaluation of the sections stained with hematoxylin
and eosin. Tumors cells adjacent to necrotic areas and cortical
areas, cells with small, regular nuclei, reactive astrocytes and
endothelial and blood cells were avoided. Invading GB cells at the
invasive edge were identified by means of their nuclear atypia and
heteropyknotic staining, consistent with cells within the tumor
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under an inverted microscope and processed immediately for
RNA isolation.
RNA extraction, miRNA microarray profiling, and data
processing
Total RNA, including small RNA, was isolated using the
mirVana miRNA isolation kit (Ambion, Austin, TX). The RNA
quality and quantity were assessed using the NanoDrop 2000
(Thermo Scientific, Waltham, MA). The integrity of RNA was
determined using a Bioanalyzer 2100 Nano LabChip kit (Agilent
Technologies, Santa Clara, CA). Samples selected for the study
contained intact RNA with a RIN$8.0. One hundred ng total
RNA was end-labeled with Cy3-pCp following the manufacturer’s
recommendations using Agilent’s miRNA Complete Labeling and
Hyb Kit (Agilent). Labeled miRNA was hybridized to Agilent’s
Human 8x15K miRNA Microarrays (V2) based on Sanger
miRbase (release 10.1). Images were captured using an Agilent
DNA Microarray Scanner set at default settings for miRNA
microarrays. Scanned TIFF images were processed using Feature
Extractor v. 10.5.1.1. Further quality control and normalization
was performed using GeneSpring GX 11 (Agilent). Signals ,1
were set to 1 due to GeneSpring’s analysis in log space, negative
values were converted as well. Values were divided by the 75th
percentile signal on that array to allow for improved comparison
between arrays.
Statistical significance of differentially expressed miRNAs
between the rim and core cell populations was determined using
a two-tail t-test followed by FDR correction using Storey’s method
[30]. Hierarchical clustering, which builds clusters based on the
hierarchy of groups, was used to visualize the prominence of
miRNAs differentiating rim and core cell populations. Hierarchi-
cal clustering of the differentially expressed miRNA was
performed using Spearman’s correlation (1-correlation) as distance
and complete linkage to group clusters. Clustering and t-test were
performed using MATLAB (MathWorks, Natick, MA).
Quantitative Reverse Transcription-PCR (qRT-PCR)
analysis of miRNAs
Complementary DNAs (cDNAs) were synthesized using 25 ng
of total RNA following the manufacturer’s directions in the
TaqMan microRNA Reverse Transcription kit and miRNA-
specific stem-loop primers (Life Technologies, Carlsbad, CA).
Quantitative PCR analyses of miRNAs and 18s ribosomal RNA
were carried out in triplicate in a 384-well plate using a Light-
Cycler 480 (Roche Applied Sciences, Indianapolis, IN) with
TaqMan fluorescence signal detection (Life Technologies) after
each cycle of amplification. Crossing points of miRNA vs. 18S
ribosomal RNA were used to calculate relative fold up-/down-
regulation in the migrating cells as previously described [13].
Adenovirus production and infection
The design and performance of a recombinant adenovirus
encoding wild-type Pyk2 was previously described [25]. This
clone, designated Pyk WT, contains the entire coding sequence
and an additional 725 base pairs of the 3’ UTR. To construct
a recombinant adenovirus encoding Pyk2 devoid of 3’ UTR,
designated Pyk 3Kb, the Pyk2 coding sequence was amplified by
PCR and ligated into the adenoviral transfer vector pShuttle-
CMV. E1-deleted adenoviruses were prepared using the Ad-Easy
systems as described [31]. Recombinant adenoviruses were
propagated in 293 cells, clonally isolated, and titered. Subcon-
fluent cultures of target cells were infected at matched multiplicity
of infection (MOI). Immunoblotting of adenovirus infected cells
was done with matched cell samples plated on the same substrate
as used for the migration assay.
Lentiviral transduction
The lentiviral vector pMIRNA1 containing a pre-miRNA-23b
sequence was obtained from System Biosciences, LLC. (Mountain
View, CA). The miRNA-23b precursor construct was packaged
into VSV-G pseudotyped lentiviral particles following transfection
of 293T cells using the pPACKH1 packaging plasmid mix (System
Biosciences) according to the manufacturer’s instructions. For
lentiviral transduction of target cells, lentiviral-containing super-
natants were collected from packaging cells at 48 and 72 hours
after transfection, concentrated by PEG precipitation, and added
to subconfluent cultures of cells with 8 mg/ml polybrene for 4–
6 hours. Forty-eight hours after infection, cells were harvested and
green fluorescence protein (GFP) positive cells were collected by
mass sorting on a FACSAria flow cytometer (BD Biosciences, San
Jose, CA).
Organotypic brain slice invasion assay
An ex vivo invasion assay on mouse brain slices was carried out as
previously described [32,33]. Animals were maintained and brain
slices obtained under a research protocol approved by the
Institutional Animal Care and Use Committee of St. Joseph’s
Hospital and Medical Center, Barrow Neurological Institute
(protocol #275, Nhan L Tran). Briefly, approximately 1610
5
glioma cells stably expressing miR-23b and GFP or empty vector
control (GFP only) were gently deposited (0.5-mL transfer volume)
onto the bilateral putamen of the 400 mm thick slices of freshly
isolated 4–6 week-old murine brains. Glioma cell invasion into the
brain slices was quantified using a LSM 5 confocal microscope and
depth of invasion (z-axis stacks) was calculated as previously
described [34].
Statistical analysis
Independent sample t-test statistical analyses of invasion and
migration assay data was performed with GraphPad Prism 5.0
(GraphPad Software, La Jolla, CA). All tests are two-tailed.
p,0.05 was considered significant.
Results
Genome-wide miRNA expression profiling demonstrates
differential expression of miRNAs in paired migratory and
migration restricted cell populations
To better understand the epigenetic program driving glioma
migration and invasion, we profiled global miRNA expression in
paired migration-restricted and migrating cell populations using
a well-characterized in vitro radial migration assay [28,29] with
seven different glioma cell lines. For each cell line, cells were plated
as a confluent, circular monolayer then allowed to migrate on
laminin for 24 hours. Migration-restricted cells from the core or
migrating cells from the rim were harvested and total RNA,
including small RNAs, was collected and profiled for miRNA
expression using Agilent 8x15K miRNA microarrays (Figure 1).
Data analysis revealed a set of 72 miRNAs that were consistently
differentially expressed between the core and the rim in all seven
glioma cell lines (Table 1 and Table 2). Hierarchical cluster
analysis of these miRNAs demonstrate that migrating and
migration-restricted cells from a range of glioma cell lines each
express a shared subset of miRNAs (Figure 2), suggesting an
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vivo.
Quantitative PCR analysis of miRNA expression in glioma
cells
As down-regulation of miRNAs in the invasive cell population
may allow for expression of genes that play important roles in
glioma migration, we chose a set of candidate miRNAs down
regulated in the invasive rim population with predicted gene
targets pertaining to migration, invasion, and survival. We
validated the results of the microarray analysis by performing
quantitative PCR (qPCR) analysis for those miRNAs of interest.
As in the microarray experiments, matched samples of migrating
cells from the rim and migration-restricted glioma cells from the
core were microdissected from the radial cell migration format.
Quantitative PCR analyses demonstrate that of the 7 miRNAs
examined, 5 were consistently down-regulated in the migrating cell
population in all the cell lines analyzed, consistent with the
microarray results (Table 3). miR-15b and miR-19 exhibited some
variability being down regulated in the invasive cell population in
3/6 and 4/6 cell lines, respectively. Notably, the expression of
miR-23b was significantly lower in the migratory cell population
relative to the migration-restricted core cells in all six of the glioma
cell lines. Among the predicted targets of miR-23b is the focal
adhesion kinase Pyk2 which we have previously demonstrated
plays a role in stimulating glioma cell migration [24,25] suggesting
down regulation of miR-23b may allow for extended expression of
Pyk2 in the invasive cell population.
Overexpression of miR-23b suppresses glioma cell
migration and invasion
To examine the effect of miR-23b expression on glioma cell
migration, SF767, SNB19, T98G and U87 glioma cell lines were
stably transduced with a recombinant lentivirus encoding a miR-
23b precursor-microRNA. Control cells were transduced with the
empty lentiviral vector alone. Stably transduced cells were
enriched by flow cytometry and increased expression of miR-
23b was validated by qPCR. The effect of miR-23b expression on
glioma cell migration was examined using the radial cell migration
assay. Overexpression of miR-23b significantly inhibited the
migration rate of all four cell lines (Figure 3A). The effect of
expression of miR-23b on glioma cell invasion was examined in
the authentic brain matrix using an ex vivo organotypic brain slice
model [32,33]. Three glioma cell lines (SF767, T98G and U87)
stably transduced with empty lentiviral vector or a recombinant
lentivirus encoding a miR-23b precursor microRNA were seeded
onto a fresh murine brain slice and allowed to invade the matrix
for 48 hr. Increased expression of miR-23b significantly inhibited
the invasion of all three of the cell lines relative to their matched
control cells (Figure 3B) indicating increased expression of miR-
23b inhibits glioma cell migration and invasion.
Figure 1. miRNA analysis of migration active and migration
restricted glioma cells in vitro. Glioma cell lines were seeded onto
10-well glass slides coated with 10 mg/ml laminin and allowed to
migrate for 24 hours. Total RNA, including small RNA, was isolated from
microdissected migrating (rim) and migration-restricted (core) cell
populations. Total RNA (100 ng) was end-labeled with Cy3 and
hybridized to Agilent human miRNA microarrays.
doi:10.1371/journal.pone.0039818.g001
Table 1. Up-regulated miRNAs in migrating glioma cells.
microRNA ID
Fold Change
(Rim vs. Core)
p-value
(T-test)
False Discovery
Rate
hsa-miR-99a* 1.99 0.00660 0.02081
hsa-miR-767-3p 1.94 0.00314 0.01455
hsa-miR-202* 1.85 0.00850 0.01999
hsa-miR-556-3p 1.79 0.00414 0.01674
hsa-miR-655 1.78 0.00353 0.01505
hsa-miR-451 1.72 0.00548 0.01963
hsa-miR-495 1.67 0.00949 0.02107
hsa-miR-579 1.66 0.00647 0.02082
hsa-miR-223 1.64 0.00775 0.02035
hsa-miR-381 1.46 0.00641 0.02104
hsa-miR-329 1.46 0.00287 0.01413
hsa-miR-769-3p 1.44 0.00861 0.01995
hsa-miR-524-3p 1.43 0.00261 0.01369
hsa-miR-93* 1.43 0.00796 0.01991
hsa-miR-220a 1.40 0.00690 0.01978
ebv-miR-BART5 1.40 0.00677 0.02015
hsa-miR-491-5p 1.39 0.00639 0.02143
hsa-miR-200c* 1.39 0.00662 0.02047
hsa-miR-133b 1.38 0.00666 0.02018
hsa-miR-19b-1* 1.37 0.00692 0.01948
hsa-miR-520h 1.37 0.00693 0.01917
hsa-miR-92b 1.35 0.00792 0.02014
hsa-miR-657 1.35 0.00801 0.01971
hsa-miR-891a 1.35 0.00818 0.01983
hsa-miR-326 1.35 0.00834 0.01991
hsa-miR-541* 1.34 0.00971 0.02126
doi:10.1371/journal.pone.0039818.t001
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glioma cell migration
To further define the role of miR-23b in the regulation of
glioma cell migration, we examined the effect of knockdown of
miR-23b expression in four glioma cell lines (SF767, SNB19,
T98G and U87) using an anti-miR-23b oligonucleotide. Trans-
fection of glioma cells with an anti-miR-23b oligonucleotide
resulted in reduction of miR-23b expression by , 90%.
Representative results are shown for T98G cells (Figure 4A).
The effect of reducing miR-23b expression on glioma cell
migration was examined using the radial migration assay. The
reduction of miR-23b expression resulted in a significant increase
in the migration rate of all four glioma cell lines relative to cell
lines expressing a control random sequence anti-miR (Figure 4B).
Clinical samples indicate lower expression of miR-23b in
the invading rim
Results from the in vitro migration assay indicate that miR-23b
expression is down regulated in the migratory cell population
relative to cells in the migration-restricted core. To determine
whether miR-23b was differentially expressed in glioblastoma cells
in vivo, we examined miR-23b expression in clinical biopsy
samples. Cells from the invasive edge or cells from the tumor
core were microdissected from tissue sections from three patient
samples (GBM 187, GBM 191 and GBM 192). Quantitative PCR
analysis revealed that miR-23b expression was markedly reduced
in the invasive edge population compared to matched cells of the
tumor core in all three patient samples (Figure 5) corroborating the
results of the in vitro assays.
Pyk2 is a target of miR-23b in glioma cells
A bioinformatics search of potential miR-23b targets using
miRBase [35] and TargetScan [36,37] revealed a conserved target
site within the 3’ UTR of the non-receptor tyrosine kinase Pyk2
(Figure 6A). Increased expression and activity of Pyk2 correlates
with advancing tumor grades in patients [38]. Furthermore, we
have previously demonstrated that knockdown of Pyk2 expression
significantly inhibited glioblastoma cell migration in vitro and
invasion ex vivo in brain slices [25]. In addition, reducing Pyk2
expression levels in glioblastoma cells significantly extends survival
in a murine intracranial xenograft tumor model [39]. To validate
that Pyk2 expression can be regulated by miR-23b, we examined
the expression of Pyk2 in miR-23b overexpressing glioma cells.
Expression of Pyk2 was significantly reduced in stably transduced
U87 and SF767 glioma cells overexpressing miR-23b relative to
Pyk2 expression in control transduced U87 and SF767 glioma cells
as assayed by immunoblotting (Figure 6B). Unlike Pyk2, the 3’
UTR of the closely related focal adhesion kinase FAK does not
contain a predicted miR-23b target site [35,36] and immunoblot-
ting indicated that increased expression of miR-23b did not
significantly alter expression of FAK in these cells. To further
examine whether Pyk2 expression is modulated by miR-23b, we
performed co-expression studies. Two recombinant adenoviruses
were assembled for these studies. Both adenoviruses encode
a FLAG epitope-tagged Pyk2 however; they differ in their
respective transcripts. In the Pyk WT construct, the transcript
includes the entire coding sequence and 725 bp of 3’ UTR that
includes the potential miR-23b target sequence. In the Pyk 3Kb
construct, the transcript is limited to the coding sequence and lacks
any 3’ UTR. Infection of parental T98G or U87 glioma cells with
matched MOI of either the Pyk2 WT or Pyk 3Kb recombinant
adenoviruses resulted in dose dependent expression of Pyk2
protein as assayed by immunoblotting (Figure 7). Infection of
Table 2. Down-regulated miRNAs in migrating glioma cells.
microRNA ID
Fold Change
(Rim vs. Core) p-value (T-test)
False Discovery
Rate
hsa-miR-16 28.26 0.00046 0.00564
hsa-miR-30c 27.03 0.00043 0.00569
hsa-miR-15b 26.93 0.00050 0.00567
hsa-let-7f 26.58 0.00009 0.00239
hsa-let-7a 26.46 0.00001 0.00140
hsa-miR-23b 26.09 0.00426 0.01677
hsa-miR-103 26.07 0.00261 0.01327
hsa-miR-107 25.97 0.00097 0.00807
hsa-miR-24 25.91 0.00332 0.01452
hsa-miR-93 25.70 0.00018 0.00348
hsa-miR-15a 25.66 0.00689 0.02011
hsa-miR-151-5p 25.66 0.00013 0.00294
hsa-miR-23a 25.51 0.00177 0.00995
hsa-miR-30b 25.46 0.00051 0.00536
hsa-let-7e 25.29 0.00002 0.00088
hsa-miR-30a 25.29 0.00363 0.01507
hsa-miR-29a 25.26 0.00625 0.02141
hsa-miR-455-3p 25.14 0.00550 0.01926
hsa-let-7b 24.90 0.00003 0.00103
hsa-miR-25 24.79 0.00020 0.00347
hsa-let-7c 24.74 0.00001 0.00075
hsa-miR-106b 24.73 0.00914 0.02058
hsa-miR-92a 24.72 0.00442 0.01700
hsa-let-7d 24.62 0.00121 0.00831
hsa-miR-125b 24.55 0.00493 0.01849
hsa-miR-125a-5p 24.47 0.00134 0.00811
hsa-miR-222 24.45 0.00520 0.01908
hsa-let-7g 24.44 0.00113 0.00847
hsa-miR-17 24.43 0.00331 0.01491
hsa-miR-20a 24.27 0.00110 0.00866
hsa-miR-29c 24.25 0.00762 0.02034
hsa-let-7i 24.20 0.00041 0.00582
hsa-miR-26a 24.13 0.00124 0.00780
hsa-miR-574-3p 23.90 0.00299 0.01426
hsa-miR-181b 23.80 0.00038 0.00606
hsa-miR-30e 23.80 0.00066 0.00611
hsa-miR-320 23.78 0.00064 0.00627
hsa-miR-99a 23.51 0.00905 0.02067
hsa-miR-424 23.45 0.00149 0.00871
hsa-miR-181a 23.19 0.00788 0.02037
hsa-miR-10b 23.13 0.00073 0.00638
hsa-miR-17* 22.90 0.00234 0.01273
hsa-miR-140-5p 22.87 0.00117 0.00836
hsa-miR-197 22.73 0.00744 0.02022
hsa-miR-151-3p 22.48 0.00002 0.00095
hsa-miR-30e* 22.27 0.00123 0.00811
doi:10.1371/journal.pone.0039818.t002
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adenovirus produced dose-dependent expression of Pyk2 protein
similar to that observed in the parental cells. In contrast,
expression of Pyk2 protein in the T98G or U87 cells over-
expressing miR-23b following infection with the Pyk WT
adenovirus was significantly reduced relative to Pyk2 expression
in the parental cells at the same MOI, substantiating that Pyk2 is
a target for miR-23b (Figure 7).
TodeterminethefunctionalrelationshipbetweenPyk2andmiR-
23b expression, we examined the capacity of increased Pyk2
Figure 2. miRNA analysis of glioma cell migration. miRNA expression in paired migration-restricted and migrating cell populations from seven
different glioma cell lines was profiled using Agilent human miRNA microarrays. Hierarchical cluster dendrogram of significant differentially expressed
miRNAs (p,0.01). Red and green color scale represents high and low expression respectively.
doi:10.1371/journal.pone.0039818.g002
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mediated by miR-23b in the radial migration assay (Figure 8).
Consistentwithearlierresults,themigratoryrateofT98Gcellswith
increased miR-23b expression was significantly reduced compared
to control transduced T98G cells. Infection of T98G miR-23b cells
with the Pyk 3Kb recombinant adenovirus significantly increased
theirmigrationraterelativetoT98GmiR-23bcellsandT98GmiR-
23b cells infected with a control adenovirus encoding ß-galactosi-
dase. Increased migratory rate was accompanied by increased
expression of Pyk2 as assayed by immunoblotting. In contrast,
infection of T989G miR-23b cells with a matched MOI of the Pyk
WT recombinant adenovirus resulted in only a modest increase in
Pyk2expressionanddidnotsignificantlyincreasethemigratoryrate
relative to the T98G miR-23b cells. Immunoblotting also indicated
thatFAKexpressionwasequivalentineachoftheexperimentalcells
indicating that FAK was unable to fully compensate for the
reduction in Pyk2 expression consistent with previous results [25].
TogethertheseresultsindicatePyk2isatargetformiR-23bandthat
miR-23b modulates glioma cell migration, in part, by regulating
Pyk2 expression.
Discussion
It is now well appreciated that miRNAs play a central role in
a broad range of physiological processes by dynamically regulating
gene expression. We have been interested in examining alterations
in gene expression profiles of invasive glioma cells to identify
potential targets to limit glioma cell invasion, increase their
susceptibility to cytotoxic agents, and improve clinical outcomes in
GB. In the current study, we investigated the potential role of
differential expression of miRNAs in glioma invasion by compar-
ing the matched large-scale, genome-wide miRNA expression
profiles of migrating and migration-restricted human glioma cells.
The major findings of this report are as follows: (1) a conserved set
of miRNAs was identified that was consistently down-regulated in
the migrating cell population relative to cells in the migration-
restricted population, (2) miR-23b was significantly down regulat-
ed in migrating glioma cells in vitro and in cells from the invasive
edge in patient tumor samples, (3) overexpression of miR-23b
significantly inhibited glioma cell migration and invasion while
inhibition of miR-23b expression significantly increased glioma
cell migration, (4) predictive miRNA target analysis revealed
a conserved miR-23b target site within the 3’ UTR of Pyk2, a non-
receptor tyrosine kinase previously implicated in the regulation of
glioma cell migration and invasion, (5) increased expression of
miR-23b reduced the expression level of Pyk2 in glioma cells but
did not significantly alter the expression level of the related focal
adhesion kinase FAK, (6) expression of a Pyk2 transcript, devoid of
the 3’UTR containing the miR23-b target sequence, in miR-23b
over-expressing cells increased Pyk2 protein expression and
partially rescued glioma cell migration. Together, these data
indicate reduced expression of miR-23b, in part, facilitates glioma
cell migration and invasion via modulation of Pyk2 expression.
The propensity of malignant glioma cells to invade into the
surrounding normal brain parenchyma precludes effective clinical
treatment. The inability to effectively target the invasive cells
virtually assures tumor recurrence. Therefore, understanding the
molecular determinants of glioma that regulate invasion is essential
for the development of new therapies and improved clinical
outcomes. While recent studies have identified a role for miRNAs
Table 3. qPCR analysis of differentially expressed miRNAs in
migrating glioma cells.
Cell
Line Fold Change (Rim vs. Core)
let-7e let-7f miR-15b miR-16 miR-19 miR-23b miR-30e
A172 22.200 21.830 0.473 22.667 0.203 21.050 23.120
SNB19 24.667 22.337 0.003 21.543 0.373 20.993 23.537
T98G 22.093 22.047 20.020 2.127 21.137 22.190 22.853
U118 20.587 20.827 21.557 22.250 20.620 22.177 20.453
U251 22.127 20.103 0.773 21.183 21.523 22.740 21.990
U87 21.533 20.120 20.903 22.073 21.750 21.160 22.137
doi:10.1371/journal.pone.0039818.t003
Figure 3. Constitutive miR-23b expression suppresses glioma cell migration and invasion. A. Effect of constitutive miR-23b expression on
glioma migration. Glioma cells stably transduced with empty vector (ctrl) or miR23b were seeded onto 10-well glass slides pre-coated with 10 mg/ml
human laminin. Cell migration was assessed over 24 hours. Data represent the average of three independent experiments and is depicted as mean 6
SD (*: p,0.01). B. Effect of constitutive miR-23b expression on glioma invasion in ex vivo murine brain slice assay. Control cells or cells constitutively
expressing miR-23b were implanted onto the bilateral putamen of mouse brain slices and observed at 48 hr. Depth of invasion was calculated from Z-
axis images collected by confocal laser scanning microscopy. The mean value of the depth of invasion was obtained from six independent
experiments and is depicted as mean 6 SD (*: p,0.01, **: p,0.05).
doi:10.1371/journal.pone.0039818.g003
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PLoS ONE | www.plosone.org 7 June 2012 | Volume 7 | Issue 6 | e39818in GB [17,18,22,40], a detailed analysis of global miRNA
expression profiles in matched samples of migrating or migra-
tion-restricted glioma cells has not been previously reported. Our
analysis of a panel of glioma cell lines identified a set of miRNAs
that were consistently down regulated in the migratory cell
population, suggesting a potential role for these miRNAs in the
regulation of migration. miR-23b was included in the set of down-
regulated miRNAs and predictive miRNA target analysis revealed
several known drivers of cell migration and invasion as potential
targets of miR-23b. Indeed, increased expression of miR-23b
significantly inhibited the migration rate of glioma cells in vitro and
invasion ex vivo in brain slices. Conversely, suppression of miR-23b
expression stimulated the migration rate of glioma cells. These
results were substantiated by the demonstration that miR-23b
expression was significantly reduced in glioma cells from the
invasive rim in patient GB samples. Similarly, recent reports have
demonstrated that miR-23b expression is significantly down
regulated in several cancers including metastatic prostate, hepa-
tocellular, bladder, and colon cancer [41,42,43,44]. Our data
indicate that alterations in miR-23b expression may also play a role
in GB invasion and progression.
Expression of miR-23b has recently been demonstrated to
regulate the expression of a set of pro-metastatic genes [44]. Our
analyses indicate that the non-receptor focal adhesion kinase Pyk2
also represents a potential target for miR-23b. Several lines of
evidence support a role for Pyk2 in glioma invasion. Expression of
Pyk2 increases with increasing tumor grade in patient GB samples
[38]. In addition, our previous studies have demonstrated that the
migration rate of glioma cells in vitro correlated positively with
Pyk2 activity [24]. Increased expression of Pyk2 increased glioma
cell migration and expression of Pyk2 is upregulated in invasive
glioma cells in situ relative to the cells in the tumor core [11,24,25].
Conversely, silencing of Pyk2 expression significantly inhibited
glioma cell migration in vitro, inhibited glioma cell invasion in brain
slices, and prolonged survival of intracranial xenografts [25,39].
Our current data indicate that miR-23b regulates Pyk2 protein
expression. Increased expression of miR-23b suppressed Pyk2
expression which correlated with a reduced glioma cell migration
rate in vitro and invasion ex vivo in brain slices. In addition, the
observed reduction of miR-23b expression in the invasive cell
population of human GBM biopsy samples is consistent with the
increased expression of Pyk2 observed in the invasive cell
population [11] and support a potential mechanism for the
maintenance of an invasive phenotype via modulation of Pyk2
expression. Future studies will seek to investigate the effect of
altering miR-23b expression on glioma cell invasion with primary
GBM xenografts [45] in orthotopic mouse models.
Cellular invasion is a dynamic process dependent upon the
interplay among diverse signaling pathways initiated by cues from
the cellular and extracellular environments [46,47]. Alterations in
miRNA expression can directly as well as indirectly regulate
signaling pathways by modulating the expression of important
signaling effectors. Our findings indicate a role for miR-23b
regulation of Pyk2 expression in glioma migration however, given
the capacity of miRNAs to bind to targets through imperfect
matching it is expected that downregulation of miR-23b alters the
Figure 4. Suppression of miR-23b by anti-miR-23b oligonucleotides enhances glioma cell migration. A. Effect of anti-miR-23b on miR-
23b expression. T98G glioma cells were transfected with 100 nM anti-miR-23b oligonucleotide or a random sequence control oligonucleotide. 48
hours after transfection, expression of miR-23b was determined by quantitative PCR. B pre-coated with 10 mg/ml human laminin 16 hours after
transfection. Cell migration was ass. Effect of anti-miR-23b expression on glioma migration. Cells were seeded onto 10-well glass slides essed over 24
hr. Bars represents the average of three independent experiments (*: p,0.05).
doi:10.1371/journal.pone.0039818.g004
Figure 5. Differential expression of miR-23b in GB patient
specimens. Surgical glioblastoma biopsy samples were sectioned,
stained, and the tumor core or invasive rim were delineated by
histological examination. Cells from the invasive rim and tumor core
populations were microdissected and total RNA, including small RNA,
was isolated. The relative abundance of miR-23b in each cell population
was determined by quantitative PCR. Results are depicted relative to
control and normalized to 18S ribosomal RNA.
doi:10.1371/journal.pone.0039818.g005
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bioinformatic analysis suggests that miR-23b can potentially
regulate the expression of over 100 genes and a recent study has
validated miR-23b targeting of a set of genes implicated in
invasion, metastasis, and angiogenesis [44]. The identity of other
miR-23b potential targets related to glioma migration and their
relationship to Pyk2 expression and signaling remains to be
determined. In this regard, it is noted that increased expression of
Pyk2 utilizing a non-targetable Pyk2 transcript in miR-23b
overexpressing cells was capable of stimulating cell migration but
did not completely rescue the migration deficit substantiating
a requirement for other miR-23b targets in glioma migration.
Moreover, since our analysis indicated that a set of miRNAs was
down regulated in the migratory cell population, it is likely that
targets of other miRNAs in this set, in addition to miR-23b targets,
also participate in the complex regulation of glioma invasion and
warrant further investigation.
Figure 6. Pyk2 is a target of miR-23b in glioma cells. A. Predicted pairing of Pyk2 3’ UTR target region (top) and hsa miR-23b (bottom). Box
highlights the exact match of positions 515-522 of Pyk2 3’ UTR with positions 2-8 (the seed plus position 8) of the mature miRNA. B. Immunoblot
analyses of Pyk2 and FAK in control transduced U87 and SF767 glioma cells (ctrl) or in U87 and SF767 cells constitutively expressing miR-23b. Cell
lysates were immunoblotted with anti-actin antibody to ensure equivalent protein loading in each lane.
doi:10.1371/journal.pone.0039818.g006
Figure 7. miR-23b targets the 39 UTR of Pyk2. Wild-type T98G and
U87 glioma cells or T98G and U87 cells constitutively expressing miR-
23b were infected with recombinant adenoviruses expressing FLAG
epitope-tagged wild-type Pyk2 (Pyk WT) or Pyk2 lacking the 3’ UTR (Pyk
3Kb). Cells were infected at the indicated multiplicity of infection (MOI).
24 hr after infection, cells were lysed, and the cell lysates were
immunoblotted with an anti-FLAG monoclonal antibody. Lysates were
immunoblotted with anti-actin antibody to ensure equivalent protein
loading in each lane.
doi:10.1371/journal.pone.0039818.g007
Figure 8. Re-expression of Pyk2 stimulates migration of miR-
23b overexpressing cells. A. T98G cells transduced with empty
vector (ctrl) were left uninfected while T98G cells overexpressing miR-
23b were infected with adenoviruses encoding ß-galactosidase, or FLAG
epitope-tagged wild-type Pyk2 (Pyk WT) or Pyk2 lacking the 3’ UTR (Pyk
3Kb) at MOI=5. Sixteen hours after infection, cells were plated onto
laminin coated slides and the migration rate determined after 24 hours.
Values are mean 6 SD of 10 replicate samples (*: p,0.05). B. Whole cell
lysates were immunoblotted with the indicated antibodies.
doi:10.1371/journal.pone.0039818.g008
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PLoS ONE | www.plosone.org 9 June 2012 | Volume 7 | Issue 6 | e39818In summary, the results of the current study assign an important
role for miR-23b expression in the regulation of glioma cell
migration, in part, through modulation of Pyk2 expression.
Additional studies will be required to identify other targets of
miR-23b and their role in the regulation of glioma cell migration
and invasion. Given the critical need for therapies that effectively
target the invasive cell component of glioma, these data suggest
that selective modulation of specific miRNAs may provide a rich
area for therapeutic development to improve clinical outcome in
GB.
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